Frank Kramer, Ph.D. is Director Biomarker Strategist in BAYER Pharma AG`s Experimental Medicine group in Wuppertal, Germany. In this role he develops, implements and executes digital, molecular and functional biomarker strategies. This includes directing and coordinating the execution of patient stratification and monitoring strategies for individual clinical trials (Phase I-IV). Before taking over the current role Dr. Kramer worked as a lab head and identified pharmaceutical targets and biomarkers in cardiovascular and pulmonary in-vitro and in-vivo models. Dr. Kramer held appointments at Wyeth, Aventis and Sanofi in Germany and Ireland in the past. He authored more than 30 peer reviewed publication and book chapters in the field of pre-clinical and clinical cardiology and biomarker research. Dr. Kramer obtained his Ph.D. at the University of Pharmacy in Frankfurt, Germany.